LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the topline results ...
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc., a molecular genomics company pioneering precision dermatology, announces the publication of a new clinical study, confirming the clinical utility of ...
Dermtech stock is up over 130% so far in 2021, and increased insurance acceptance is just one reason it could be a five-bagger in the next five years. The clinical data for its melanoma detection ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback